Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
PEG-modified Drugs (Recombinant Proteins-Polypeptides) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Nonmyeloid Malignancy and Slow Growth in Children are the major drivers for the industry.
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PEG-modified Drugs (Recombinant Proteins-Polypeptides), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PEG-modified Drugs (Recombinant Proteins-Polypeptides) introduction, etc. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of PEG-modified Drugs (Recombinant Proteins-Polypeptides) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
PEG-modified Drugs (Recombinant Proteins-Polypeptides) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Nonmyeloid Malignancy and Slow Growth in Children are the major drivers for the industry.
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Segment by Application
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PEG-modified Drugs (Recombinant Proteins-Polypeptides), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PEG-modified Drugs (Recombinant Proteins-Polypeptides) introduction, etc. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of PEG-modified Drugs (Recombinant Proteins-Polypeptides) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices